Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

The Omaha resident, who has adopted and fostered a number of dogs, had traveled to the shelter hoping to adopt a Japanese ...

Pfizer's marstacimab (Hympavzi), an IgG1 monoclonal antibody that helps promote clotting, remains on the market. The drug was ...

Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for ...

According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and ...

Pfizer said on Thursday it will end global development of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors. Beqvez was approved in the U.S. last year, for the ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in ...

The hemophilia market is expected to experience significant growth due to advancements in gene therapy, innovative treatments, and an increasing focus on personalized medicine. Rising awareness and ...

Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.